Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20122 + adebrelimab
- Development stage
- Phase 1
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HS-20122 + adebrelimab is an investigational combination therapy being developed by Hansoh BioMedical for the treatment of advanced non-small cell lung cancer (NSCLC). The combination consists of HS-20122, a research-stage compound, and adebrelimab (also known as adbrelimab), a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1). Adebrelimab is an IgG4 subtype antibody that blocks the interaction between PD-L1 and its receptors, PD-1 and B7.1, thereby restoring T-cell mediated anti-tumor immune responses. The combination is currently being evaluated in Phase Ib clinical trials to assess safety, efficacy, and pharmacokinetics in patients with locally advanced or metastatic NSCLC, particularly those with wild-type EGFR. While adebrelimab is approved in China for extensive-stage small cell lung cancer, HS-20122 remains an early-stage asset with limited publicly disclosed mechanistic details.
- Other names
- HS-20122 + adbrelimab
02
Targets
EGFR (Epidermal growth factor receptor)CD274 (Programmed cell death protein 1 ligand 1)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on HS-20122 + adebrelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20122 + adebrelimab.